Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T cells for relapsed/refractory hematologic malignancies
ChiCTR2000040368Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Jun 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LV20.19 CAR-T in hematopoietic malignancies and lymphoma, sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoints: Remission rate and Adverse effects rate. Started Jun 2019; status: recruiting.
02
Drugs
LV20.19 CAR-T
03
Conditions
hematopoietic malignancieslymphoma
Beyond the preview
Go deeper on ChiCTR2000040368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040368.